Roche's Herceptin provides impressive survival benefit in HER2-positive advanced gastric cancer
Friday, September 25, 2009 09:00 IST Basel
A detailed analysis of the phase-III ToGA study revealed an unprecedented survival benefit for patients whose tumours exhibited a particularly high level of HER2 when Roche's Herceptin (trastuzumab) was added to standard